Evaluation method based non-invasive imaging in Parkinson’s disease models

다국어 초록 (Multilingual Abstract)

Parkinson’s disease (PD) is the second most common neurodegenerative movement disorder and is characterized by the loss of dopaminergic neurons in the nigrostriatal system. To monitor the PD, PET with [18F]FP-CIT for the dopamine transporter (DAT) has become a widely used tool. For PD study, invaluable tools are neurotoxin-based animal models. To validate the usefulness of these animal models in DAT imaging, we discuss the evaluation of these models. To develop most classical neurotoxin PD animal models, we injected 6-hydroxydopamine (6-OHDA) into the substantia nigra of mouse or treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by oral routes. After that, [18F]FP-CIT PET imaging were acquired. The changes in [18F]FP-CIT uptake were also analyzed using PMOD software. For analysis of 6-OHDA induced PD model, we used [18F]FP-CIT binding ratio observed in the right/left striatum of the mice. Ratio average of 6-OHDA induced group was 0.477 as compare with control group ratio average 0.987. When MPTP-induced PD model were analyzed by [18F]FP-CIT binding ratio in the average of left and right striatum with the cerebellum as a reference, MPTP-treated group was 1.944 compared to average of the control group ratio 2.924. In conclusion, the evaluation of each PD model with non-invasive imaging has shown to be a valuable objective of PD research. In the future, these analyzes to preclinical drug evaluation may be suitable for development of new treatment.